A new treatment option for severe hypoglycaemia for children and adults living with diabetes
Represents Tetris Pharma’s first launch in European Union
Arecor Therapeutics plc, Calculus portfolio company, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd has today launched Ogluo® (glucagon prefilled autoinjector pen) as a treatment for severe hypoglycaemia in children and adults living with diabetes in Germany. Germany is a significant diabetes market and represents the first launch of Ogluo® in the European Union.
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia. There are an estimated 6.2 million adults living with diabetes in Germany.
Today’s launch in Germany builds on the roll-out of Ogluo® in Great Britain. As part of the pan-European commercialisation programme, Tetris Pharma intends to commercialise Ogluo® in core European markets. The Company is currently in discussions with various health authorities across Europe to ensure timely launches in other major European countries.
Prof. Barbara Ludwig, Universitätsklinikum Carl Gustav Carus. Dresden, commented:
“The risk of severe hypoglycaemia can be frightening for people living with diabetes, as well as for family, friends and carers. With Ogluo® being made available in Germany, it gives people living with diabetes another ready-to-use option.”
Dr Shafiq Choudhary, Managing Director of Tetris Pharma, commented:
“With the launch of Ogluo® in Germany, Tetris Pharma has achieved a significant milestone through the commercialisation of our flagship product. A severe hypoglycaemic event can be very frightening, not only for the patients, but for those around them who have to act quickly. The launch of Ogluo® means that patients living with diabetes in Germany who may experience severe hypoglycaemia will now have a new option to tackle those events. We look forward to expanding our reach within Europe over the coming months to bring this new treatment to people living with diabetes.”